12:00 AM
 | 
Jun 29, 2009
 |  BioCentury  |  Product Development

Unloading HCV

Innate Pharma S.A. was to announce the first clinical data this week for a gamma-9 delta-2 T cell agonist to treat HCV. The results provide the first human proof of concept for its candidate against the target, although the company will need to do further work to show a clinical benefit and determine where in the HCV regimen IPH 1101 could be used.

HCV treatments range from immune modulators such as interferon (IFN) alpha to direct-acting antivirals like protease and polymerase inhibitors. Innate co-founder, President and CEO Herve Brailly said IPH 1101 is an immunomodulator that works by activating gamma-9 delta-2 T cells, a subset of T lymphocytes. This in turn triggers the production and release of soluble cytokines, such as IFN gamma and monocyte...

Read the full 617 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >